News coverage about Enzymotec (NASDAQ:ENZY) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Enzymotec earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.7434583193254 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Enzymotec (NASDAQ:ENZY) traded down $0.02 during trading on Wednesday, reaching $11.85. 98,500 shares of the company’s stock traded hands, compared to its average volume of 120,557. The company has a market capitalization of $277.62, a P/E ratio of -43.89, a PEG ratio of 3.19 and a beta of 1.22. Enzymotec has a 1-year low of $6.30 and a 1-year high of $12.35.
Enzymotec (NASDAQ:ENZY) last posted its quarterly earnings results on Wednesday, November 15th. The biotechnology company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.03). The business had revenue of $13.67 million during the quarter, compared to the consensus estimate of $14.36 million. Enzymotec had a return on equity of 1.24% and a net margin of 2.32%. equities research analysts forecast that Enzymotec will post 0.05 EPS for the current year.
A number of research analysts have recently commented on ENZY shares. Jefferies Group restated a “hold” rating and set a $11.50 price target on shares of Enzymotec in a research report on Thursday, October 19th. Zacks Investment Research upgraded shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Wells Fargo & Co upped their target price on shares of Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a research report on Monday, October 30th. Finally, BidaskClub lowered shares of Enzymotec from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. One analyst has rated the stock with a sell rating and four have given a hold rating to the stock. The company has a consensus rating of “Hold” and an average target price of $11.75.
COPYRIGHT VIOLATION WARNING: “Enzymotec (NASDAQ:ENZY) Receives News Impact Score of 0.17” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/14/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-enzymotec-enzy-stock-price-3.html.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.